S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
NASDAQ:RPTX

Repare Therapeutics (RPTX) Stock Price, News & Analysis

$6.60
-0.06 (-0.90%)
(As of 02/28/2024 ET)
Today's Range
$6.38
$6.76
50-Day Range
$6.12
$8.41
52-Week Range
$3.08
$13.85
Volume
121,037 shs
Average Volume
169,245 shs
Market Capitalization
$278.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.6% Upside
$17.33 Price Target
Short Interest
Healthy
2.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.33mentions of Repare Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.26) to ($2.93) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.66 out of 5 stars

Medical Sector

274th out of 958 stocks

Pharmaceutical Preparations Industry

124th out of 450 stocks


RPTX stock logo

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

RPTX Stock Price History

RPTX Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Recap: Repare Therapeutics Q4 Earnings
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
RPTX Mar 2024 7.500 call
Repare Therapeutics Inc (RPTX)
EBS Sep 2024 7.500 put
EBS Jun 2024 1.000 put
Repare Therapeutics to Regain Global Rights to Camonsertib
See More Headlines
Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RPTX
Fax
N/A
Employees
180
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$17.33
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+162.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-29,050,000.00
Net Margins
-173.09%
Pretax Margin
-163.40%

Debt

Sales & Book Value

Annual Sales
$131.83 million
Book Value
$6.66 per share

Miscellaneous

Free Float
30,123,000
Market Cap
$278.06 million
Optionable
Optionable
Beta
0.60

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Lloyd Mitchell SegalMr. Lloyd Mitchell Segal (Age 60)
    President, CEO & Director
    Comp: $913.39k
  • Dr. Michael Zinda Ph.D. (Age 53)
    Executive VP & Chief Scientific Officer
    Comp: $641.53k
  • Dr. Maria Koehler M.D. (Age 67)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $682.8k
  • Dr. Daniel Durocher Ph.D.
    Co-Founder
  • Dr. Frank Sicheri Ph.D.
    Co-Founder
  • Dr. Agnel Sfeir Ph.D.
    Co-Founder
  • Mr. Steve Forte (Age 45)
    Executive VP & CFO
    Comp: $608.52k
  • Mr. Daniel Belanger
    Executive Vice President of Human Resource
  • Mr. Cameron Black
    Executive Vice President of Discovery
  • Dr. Kim A. Seth Ph.D.
    Executive VP & Chief Business Officer














RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RPTX shares.
View RPTX analyst ratings
or view top-rated stocks.

What is Repare Therapeutics' stock price target for 2024?

4 brokers have issued 12-month target prices for Repare Therapeutics' stock. Their RPTX share price targets range from $10.00 to $25.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 162.6% from the stock's current price.
View analysts price targets for RPTX
or view top-rated stocks among Wall Street analysts.

How have RPTX shares performed in 2024?

Repare Therapeutics' stock was trading at $7.30 at the start of the year. Since then, RPTX shares have decreased by 9.6% and is now trading at $6.60.
View the best growth stocks for 2024 here
.

Are investors shorting Repare Therapeutics?

Repare Therapeutics saw a decrease in short interest during the month of February. As of February 15th, there was short interest totaling 812,500 shares, a decrease of 52.8% from the January 31st total of 1,720,000 shares. Based on an average trading volume of 222,800 shares, the short-interest ratio is currently 3.6 days. Currently, 2.8% of the shares of the company are short sold.
View Repare Therapeutics' Short Interest
.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.12. The business had revenue of $0.28 million for the quarter, compared to analysts' expectations of $0.20 million. Repare Therapeutics had a negative net margin of 173.09% and a negative trailing twelve-month return on equity of 38.60%.

What ETF holds Repare Therapeutics' stock ?

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and

When did Repare Therapeutics IPO?

(RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (24.53%), Blue Owl Capital Holdings LP (7.41%), ARK Investment Management LLC (6.70%), GSA Capital Partners LLP (0.34%), Vanguard Group Inc. (0.15%) and Harbor Capital Advisors Inc. (0.11%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends
.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 2/29/2024 by MarketBeat.com Staff